Myovant Sciences Ltd. PSLRA Notice

Weiss Law announces that on September 13, 2023, they filed a class action lawsuit in the United States District Court for the Southern District of New York (“Court”), captioned Zappia v. Myovant Sciences Ltd. et al. Case 1:23-cv-08097, on behalf of a class (“Class”) of individuals and entities that held common stock of Myovant Sciences, Ltd. (“Myovant”) as of the close of business on January 20, 2023 (“Class Period”), asserting claims under Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, and Securities and Exchange Commission Rule 14a-9, in connection with the acquisition of Myovant Sciences, Ltd. by Sumitovant Biopharma Ltd. for an unfair price.

Investors are hereby notified that not later than 60 days after the date of this notice, any member of the purported Class may move the Court to serve as lead plaintiff of the purported Class in this action.

If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights with respect to the pending action, please contact us by phone at (888) 593-4771, or via email at stockinfo@weisslawllp.com.

You may view a copy of the complaint here.

‍

About Weiss Law

Weiss Law has litigated thousands of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

‍

Contact:

Weiss Law

Michael A. Rogovin

Toll Free 888.593.4771

stockinfo@weisslawllp.com

www.weisslawllp.com

Other Cases

April 5, 2024

Shockwave Medical, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Shockwave Medical, Inc. (“Shockwave” or the “Company”) (NASDAQ: SWAV), in connection with its acquisition by Johnson & Johnson (NYSE: JNJ). Under the merger agreement, the Company’s shareholders will receive $335.00 per share. The transaction is valued at approximately $13.1 billion.

Join Case →

April 4, 2024

ChampionX Corporation Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of ChampionX Corporation (“ChampionX” or the “Company”) (NASDAQ: CHX) in connection with its acquisition by Schlumberger Limited (“Schlumberger”)(NYSE: SLB). Under the terms of the merger agreement, the Company’s shareholders will receive 0.735 shares of Schlumberger common stock for each share of ChampionX common stock owned, representing implied per-share consideration of $40.32 based upon Schlumberger’s April 3, 2024 closing price of $54.86.

Join Case →

April 4, 2024

Endeavor Group Holdings, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Endeavor Group Holdings, Inc. (“Endeavor Group” or the “Company”) (NYSE: EDR), in connection with its acquisition by Silver Lake. Under the merger agreement, the Company’s shareholders will receive $27.50 per share.

Join Case →